Browse this section for recent public health research and data from India and the world.
The nearly 40 million people living with HIV (PLWH) worldwide, are gravely concerned about the impact of COVID-19 . This review of current literature did not find evidence of higher prevalence of COVID-19 amongst PLWH, but there is equivocal data on increased mortality and worse clinical outcomes. Having HIV does not confer protection against severe manifestations of COVID-19. Several studies looking at antiretroviral drugs against HIV to treat COVID-19 have shown no mortality benefit. Thus, there is no indication to change antiretroviral therapy (ART) regimens among virologically suppressed PLWH to prevent COVID-19. HIV care delivery has been adversely impacted in several countries during this pandemic but has created an opportunity for accelerating effective strategies such as multi-month ART. Decentralizing HIV care in low-resource settings and incorporating telemedicine in high-resource settings will be critical in mitigating shocks to healthcare systems in the future. This is a useful review for policy makers. Click here to read the document.